Acadia Pharmaceuticals Inc. announced that its President, Srdjan (Serge) Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year. A search for a successor to Dr. Stankovic is ongoing. Following his retirement, Dr. Stankovic will provide consulting and advisory services for Acadia on a part-time basis.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.84 USD | -0.37% |
|
-3.04% | -52.68% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.68% | 2.46B | |
+48.60% | 57.87B | |
+41.65% | 40.25B | |
-6.70% | 39.94B | |
-5.96% | 28.54B | |
+13.01% | 26.4B | |
-20.03% | 19.33B | |
+31.63% | 12.4B | |
+0.48% | 12.23B | |
+25.11% | 12.2B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Acadia Pharmaceuticals Inc. Announces Retirement of Srdjan Stankovic as President